510(k) Report

510(k) · Cleared

Cleared

Hydragel 6 CSF Kit

K981048510(k) TraditionalCleared Oct 7, 1998201-day reviewClass II21 CFR 866.5510

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Morax · CFF Immunoelectrophoretic, Immunoglobulins, (G, A, M)

Cleared on Oct 7, 1998 after a 201-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Oct 7, 1998
Review
201 days
Class
Class II
Product code
CFF
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K981048Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CFF? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CFF device

  1. #1 K203184 HYDRASHIFT 2/4 isatuximabscore 2.3 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All CFF devices

CFF Immunoelectrophoretic, Immunoglobulins, (G, A, M): FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · CFF

1in 2021

2009: 22011: 12012: 22015: 12016: 12018: 12019: 22021: 1
2007high 2 (2009) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CFF

Too few CFF 510(k)s in any year since 2007 to give a median.

Recalls per year · CFF

1in 2022

2017: 12022: 1
2007high 1 (2017) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · CFF

1in 2021

2012: 12021: 1
2007high 1 (2012) · low 0 (2007)2025

MAUDE reports naming product code CFF, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20092—00
20100—00
20111—00
20122—01
20130—00
20140—00
20151—00
20161—00
20170—10
20181—00
20192—00
20200—00
20211—01
20220—10
20230—00
20240—00
20250—00
20260—0—

What is it indicated for?

The HYDRAGEL 6 CSF kit is designed for the qualitative detection of "oligoclonal® bands in the electrophoretic patterns of cerebrospinal fluid (CSF). and confirmation of their immunoglobulin character. The use of anti-immunoglobulin antisera permits to prove or disprove the “true”, lg- character of oligoclonal banding. Visual, comparative interpretation of immunofixation patterns of immunoglobulins in high resolution separations of CSF and serum proteins…

Read the full statement (161 words)

The HYDRAGEL 6 CSF kit is designed for the qualitative detection of "oligoclonal® bands in the electrophoretic patterns of cerebrospinal fluid (CSF). and confirmation of their immunoglobulin character. The use of anti-immunoglobulin antisera permits to prove or disprove the “true”, lg- character of oligoclonal banding. Visual, comparative interpretation of immunofixation patterns of immunoglobulins in high resolution separations of CSF and serum proteins from the same patient aliows detection of intrathecal synthesis of immunoglobulins.

The HYDRAGEL 6 CSF kit is indicated when certain diseases of the central nervous system (CNS), such as multiple sclerosis, are suspected and the detection of oligoclonal banding and inflammatory processes (intrathecal synthesis of immunoglobulins) can aid to the diagnosis.

Depending on the selection of detecting antisera (anti IgG, anti-igA and/or anti-igM) two to six CSF - serum sample pairs can be run on each gel.

The use of enzyme labeled antibodies increases the sensitivity of detection so that the analysis can be generally performed on unconcentrated CSF.

Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K981048: Hydragel 6 CSF Kit.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K981048

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026